Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

New Equilibrium Biosciences

Request full access

Drug discovery for intrinsically disordered proteins

Boston, United StatesFounded 2019Biotech & Life Sciences

About New Equilibrium Biosciences

New Equilibrium Biosciences, founded in 2019, is a biotechnology firm focused on the rational drug design for a class of proteins that have historically been difficult to target. The company was established by Dr. Virginia Burger, who serves as the CEO, and Dr. Peter Tompa, who is the Chair of the Scientific Advisory Board. Dr. Burger's background includes postdoctoral research in intrinsically disordered protein (IDP) biophysics at MIT and leading scientific collaborations at the AI drug discovery company XtalPi. Dr. Tompa is a distinguished professor and researcher who has been instrumental in the IDP field since its emergence, having authored the first monograph on the subject and organized the first conference in the field.

The company's core technology is a computational-experimental platform that merges artificial intelligence with biophysics to analyze intrinsically disordered proteins (IDPs). These shapeshifting proteins lack a fixed structure, which has made them challenging targets for traditional structure-based drug design methods. New Equilibrium's platform aims to reveal previously invisible conformations and transient binding pockets on these IDPs, thereby enabling the design of new drug candidates. By encoding quantum chemistry in AI models and augmenting physics-based simulations, the company can model large protein systems over extended timescales to identify structural details that can inform drug discovery.

New Equilibrium's business model is centered on discovering and developing lead drug candidates to address life-threatening diseases, with a specific focus on cancers and neurodegenerative disorders where IDPs are implicated. The company seeks to accelerate its internal research and development programs while also exploring strategic partnerships with other pharmaceutical and biotechnology organizations. After initial grants from the National Science Foundation and Massachusetts Life Sciences Center, and a pre-seed round from the Petri Life Sciences Incubator, the company secured a significant $10 million seed funding round in 2021 led by RA Capital Management. This capital was intended to scale up its R&D facilities, expand the team, and advance its programs targeting IDPs.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
54.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Mar 2021 $10M $40M RA Capital Management · Petri —
SEED✓Equity / VC Jun 2020 $250K $1M Petri —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

New Equilibrium Biosciences website traffic

Latest recorded traffic for New Equilibrium Biosciences is 930 monthly website visits, up 4550% over the last three months. New Equilibrium Biosciences's team grew 0% over the past year.

Latest monthly visits930 3-month web change+4550% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

New Equilibrium Biosciences in the Boston ecosystem

Live from Dealroom

The New Equilibrium Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

Other known investors1 additional known investor

Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇧🇪 Belgium100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about New Equilibrium Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See New Equilibrium Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.